Kiora Pharmaceuticals Inc (KPRX): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of KPRX were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No KPRX insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
KPRX short interest
Low short interest. 1.3% of KPRX shares are sold short: about 1 share in 78. Over the last 12 reports the number of shares short went up 157%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 56,588 KPRX shares were sold short, 1.3% of the shares outstanding, up 1248.6% from the report before. At the average daily volume of 67,008 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 56,588 | 1.28% | +1249% | 67,008 | 1.0 |
| Oct 15, 2026 | 4,196 | 0.09% | +22% | 14,326 | 1.0 |
| Sep 30, 2026 | 3,432 | 0.08% | -15% | 14,391 | 1.0 |
| Sep 15, 2026 | 4,019 | 0.09% | +14% | 11,966 | 1.0 |
| Aug 31, 2026 | 3,518 | 0.08% | +20% | 14,958 | 1.0 |
| Aug 14, 2026 | 2,943 | 0.07% | -24% | 19,567 | 1.0 |
| Jul 31, 2026 | 3,860 | 0.10% | -54% | 25,979 | 1.0 |
| Jul 15, 2026 | 8,310 | 0.21% | +16% | 12,301 | 1.0 |
| Jun 30, 2026 | 7,148 | 0.18% | -66% | 29,227 | 1.0 |
| Jun 15, 2026 | 20,871 | 0.53% | +15% | 21,665 | 1.0 |
| May 29, 2026 | 18,090 | 0.46% | -18% | 34,412 | 1.0 |
| May 15, 2026 | 21,999 | 0.56% | -29% | 92,494 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Kiora Pharmaceuticals company events
Kiora Pharmaceuticals filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 29, 2026.
- Oct 29, 2026AgreementKiora Pharmaceuticals, Inc. entered into an Exclusive License Agreement with Senju Pharmaceutical Co., Ltd. to license a late-stage neuroprotective, oral small-molecule calpain inhibitor. Filing
- Sep 8, 2026LeadershipKiora Pharmaceuticals Inc. appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs of the Company, effective as of the Effective Date. Filing
- Aug 19, 2026AgreementKiora Pharmaceuticals, Inc. entered into an Exclusive License and Development Agreement with Chong Jun Dang Pharmaceutical Corporation with respect to the Company’s KIO-301 molecular photoswitch product. Filing
- Aug 7, 2026ResultsReleased financial results. Filing
- Jun 18, 2026AnnouncementShared information with investors. Filing
- Jun 11, 2026LeadershipKiora Pharmaceuticals, Inc. held its 2026 annual meeting of stockholders. Filing
- May 8, 2026ResultsReleased financial results. Filing
- Apr 7, 2026AgreementKiora Pharmaceuticals, Inc. entered into a securities purchase agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell to the Purchasers, and the Purchasers agreed to purchase from the Company (i) 438,471 shares of the Company’s Common Stock, par value… Filing
- Apr 2, 2026LeadershipEric J. Daniels, M.D., MBA, the Chief Development Officer of Kiora Pharmaceuticals, Inc., notified the Company that he will resign as Chief Development Officer effective as of April 17, 2026 to pursue another opportunity. Filing
- Mar 25, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Kiora Pharmaceuticals financials
Famous investors that hold KPRX
3 of the 50 well-known investors we track reported holding KPRX in their latest 13F filing. The largest position is Israel Englander's, worth $453K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Israel Englander · Millennium Management | Q3 2026 | 176,784 | $453K | 0.0% | +138% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 86,739 | $222K | 0.0% | -25% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 37,200 | $95.2K | 0.0% | +25% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named KPRX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Alyeska Investment Group, L.P. | 13G/A | 5.0% |
| Nov 16, 2026 | Alyeska Investment Group, L.P. | 13G/A | 5.0% |
Questions about Kiora Pharmaceuticals Inc (KPRX) stock
Are KPRX insiders buying or selling?
No KPRX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in KPRX?
As of Oct 30, 2026, 56,588 KPRX shares were sold short, 1.3% of the shares outstanding, up 1248.6% from the report before. At the average daily volume of 67,008 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold KPRX?
3 of the 50 well-known investors we track reported KPRX in their latest 13F filing, including Israel Englander, Ken Griffin, Jim Simons. The largest position is worth $453K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.